Why Xeris Might Surprise This Earnings Season
| XERS Stock | USD 5.58 0.05 0.89% |
Slightly above 62% of Xeris Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Xeris Pharmaceuticals stock suggests that many investors are alarmed at this time. Xeris Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Xeris Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Xeris |
Xeris is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Read at zacks.com
 |
Xeris Pharmaceuticals Fundamental Analysis
We analyze Xeris Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xeris Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xeris Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Xeris Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Xeris Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Xeris Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Xeris Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Xeris Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Xeris Pharmaceuticals Related Equities
| IBRX | Immunitybio | 20.86 | ||||
| MCRB | Seres Therapeutics | 4.11 | ||||
| PLX | Protalix Biotherapeutics | 4.03 | ||||
| XFOR | X4 Pharmaceuticals | 3.85 | ||||
| CDTX | Cidara Therapeutics | 3.75 | ||||
| INZY | Inozyme Pharma | 3.13 | ||||
| MREO | Mereo BioPharma | 1.69 | ||||
| DAWN | Day One | 0.86 | ||||
| PDSB | PDS Biotechnology | 0.81 | ||||
| TERN | Terns Pharmaceuticals | 0.65 | ||||
| HOOK | Hookipa Pharma | 1.64 | ||||
| ELEV | Elevation Oncology | 7.14 | ||||
| HEPA | Hepion Pharmaceuticals | 11.59 |
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.